Gracell Biotechnologies Inc. (GRCL)
$10.25
$0.00 (0.00%)As on 22-Feb-2024 09:30EDT
Market cap
$990 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
4.4
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-334 Mln
-
ROE
-0.3 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-1.6
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-27.9
-
Face value
--
-
Shares outstanding
96,572,400
6 Years Aggregate
CFO
CN¥-1,182.60 Mln
EBITDA
CN¥-1,386.35 Mln
Net Profit
CN¥-1,960.50 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Gracell Biotechnologies (GRCL)
| 2.1 | 2.6 | 109.6 | 390.4 | -26.8 | -- | -- |
|
BSE Sensex*
| -9.1 | -1.5 | 2.9 | -3.6 | 5.9 | 6.0 | 10.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
|---|---|---|
|
Gracell Biotechnologies (GRCL)
| 336.5 | -61.9 |
|
S&P Small-Cap 600
| 13.9 | -17.4 |
|
BSE Sensex
| 18.7 | 4.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Gracell Biotechnologies (GRCL)
|
10.3 | 989.9 | 0.0 | -497.0 | -- | -35.1 | -- | 4.4 |
| 2.4 | 140.4 | 3.1 | -88.4 | -1,666.4 | -256.8 | -- | 5.3 |
Shareholding Pattern
View DetailsAbout Gracell Biotechnologies (GRCL)
Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled... dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in phase 1 clinical trial for the treatment of relapsed or refractory (r/r) B cell acute lymphoblastic leukemia (B-ALL) in adult; and GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult T cell acute lymphoblastic leukemia. The company's product candidates also comprise GC007g, a donor-derived CD19-directed allogeneic CAR-T cell therapy that is in Phase 2 clinical trial for the treatment of r/r B-ALL; and GC502, a TruUCAR-enabled dual CD19- and CD7 -directed, off-the-shelf allogeneic CAR-T product candidate, which is in Phase I trial for the treatment of B-cell malignancies. In addition, it has a portfolio of earlier stage product candidates targeting various cancer indications, such as hematologic cell malignancies and solid tumors. Gracell Biotechnologies Inc. was incorporated in 2017 and is headquartered in Suzhou, China. As of February 22, 2024, Gracell Biotechnologies Inc. operates as a subsidiary of AstraZeneca Treasury Limited. Read more
-
Founder, Chairman & CEO
Dr. Wei Cao BM, Ph.D.
-
Founder, Chairman & CEO
Dr. Wei Cao BM, Ph.D.
-
Headquarters
Suzhou
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Gracell Biotechnologies (GRCL)
What is the current share price of Gracell Biotechnologies Inc (GRCL) Today?
The share price of Gracell Biotechnologies Inc (GRCL) is $10.25 (NASDAQ) as of 22-Feb-2024 09:30 EDT. Gracell Biotechnologies Inc (GRCL) has given a return of -26.83% in the last 3 years.
What is the current PB & PE ratio of Gracell Biotechnologies Inc (GRCL)?
Since, TTM earnings of Gracell Biotechnologies Inc (GRCL) is negative, P/E ratio is not available.
The P/B ratio of Gracell Biotechnologies Inc (GRCL) is 4.39 times as on 28-Aug-2026, a 15 discount to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2022 |
-0.26 |
0.11 |
2021 |
-0.85 |
0.22 |
2020 |
-- |
-- |
2019 |
-- |
-- |
2018 |
-- |
-- |
What is the 52 Week High and Low of Gracell Biotechnologies Inc (GRCL)?
The 52-week high and low of Gracell Biotechnologies Inc (GRCL) are Rs -- and Rs -- as of 02-Sep-2026.
What is the market cap of Gracell Biotechnologies Inc (GRCL)?
Gracell Biotechnologies Inc (GRCL) has a market capitalisation of $ 990 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Gracell Biotechnologies Inc (GRCL)?
Before investing in Gracell Biotechnologies Inc (GRCL), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.